AstraZeneca (NASDAQ:AZN) is trading down 0.26% at 8129.00 Britain’s competition regulator is reviewing AstraZeneca (NASDAQ:AZN)’s $39 billion buyout of U.S.-based Alexion (NASDAQ:ALXN) on concerns it could reduce competition in the UK market or elsewhere. The UK’s Competition and Markets Authority (CMA) said on Tuesday it was inviting comments from...